BTIG initiated coverage of GE HealthCare with a Neutral rating and no price target. With the shares up 34% since the spinoff, the firm sees "limited room for upside." GE HealthCare’s organic growth in fiscal 2022 came out to 7.3% year-over-year, but on the back of an easier compare, the analyst tells investors in a research note. Given the run in the shares, the firm thinks it is prudent to remain Neutral until the company establishes a longer track record of independent execution.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on GEHC:
- ICU teams with Linden Capital for Medtronic assets bid, Reuters reports
- GE HealthCare initiated with an Outperform at Evercore ISI
- GE HealthCare stock had a great start, more gains lie ahead, Barron’s says
- General Electric price target raised to $96 at BofA ahead of investor day
- GE HealthCare, Advantus Health in pact to provide HTM services